Abstract
Contrast-enhanced CT or MRI are used as a gold standard imaging modalities in the detection and characterization of renal masses. On the other hand, the role of FDG PET/CT in evaluating primary or metastatic cancers of the kidney is limited due to the excretion of FDG through urinary tract. We reported the FDG PET/CT of a lung cancer patient with multiple metastases in both kidneys which were missed in previous PET/CT, and underestimated on sequential diagnostic abdominal CT study.Conflict of interest:None declared.
Highlights
The Kidney is the fifth most common site of metastasis in the body [1]
Contrast-enhanced CT or MRI is widely used in the detection and characterization of renal masses. 18F-FDG PET/CT is extensively used in oncology, but its utilization in evaluating primary or metastatic involvement of the kidney is limited, because physiological excretion of 18F-FDG through urinary tract may interfere with tumor imaging
We report the 18F-FDG PET/CT of a lung cancer patient with multiple bone and soft tissue metastases including both kidneys which were missed in the previous PET/CT study, and underestimated on the sequential abdominal CT study
Summary
Molecular Imaging and Radionuclide Therapy 2013;22(3): 109-111 DOI: 10.4274/Mirt.130 Is the Value of FDG PET/CT in Evaluating Renal Metastasis Underestimated? A Case Report and Review of the Literature FDG PET/BT’nin Böbrek Metastazlarını Değerlendirmedeki Değeri Hafife mi Alınıyor? Olgu Sunumu ve Literatürün Gözden Geçirilmesi Mustafa Aras, Fuat Dede, Tunç Önes, Sabahat İnanır, Tanju Yusuf Erdil, Halil Turgut Turoğlu Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call